– USA, OH – CinCor Pharma, Inc. today announced the appointment of current Board member Marc de Garidel as CEO, effective immediately, replacing Dr. Jon Isaacsohn who will continue as CSO and as a member of the Board of Directors.
“Marc brings deep global biopharmaceutical company experience to the executive team,” said Board Chairman, Dr. James Healey. “He has already made significant contributions to CinCor during his short tenure on our Board. We expect that to continue in his new role as CEO. I also want to thank Jon for his contributions as CEO and look forward to his continued insights as CSO and a fellow Board member.”
About Marc de Garidel
Prior to joining CinCor, Marc de Garidel l served as CEO of Corvidia Therapeutics, a private Boston-based cardiorenal-focused clinical-stage company that was acquired by Novo Nordisk in August 2020 for $2.1 billion. From 2010 to 2016, he served as CEO and Chairman of Ipsen SA’s board of directors, where he led a significant transformation of the Company, effecting a three-fold increase in market capitalization, launching the blockbuster oncology drug Somatuline® Depot (lanreotide) in the U.S., and completing the ex-U.S. commercialization deal with Exelixis on CABOMETYX (cabozantinib). Mr. de Garidel still serves as Chairman of Ipsen’s Board of Directors. Before joining Ipsen, Mr. de Garidel spent 15 years at Amgen Inc., initially joining as the company’s chief financial officer in Europe and ultimately leading the large international south region as a regional vice president. He began his career at Eli Lilly and Company, where he worked in the U.S., France, and Germany in a variety of roles in sales, marketing, finance, and human resources. Other active Board roles held by Mr. de Garidel include Claris Biotherapeutics, Inc. and AZTherapies, Inc.
“Our lead asset, CIN-107, has the potential to be one of the most significant therapeutic advances for treating patients with hypertension and primary aldosteronism in decades,” said Mr. de Garidel. “I have been impressed with the team’s commitment to advancing it expeditiously through clinical development. I look forward to working with the executive team to bring CIN-107 to patients who would benefit.”
Mr. de Garidel received a master’s degree in Civil Engineering from Ecole Spéciale des Travaux Publics in Paris, a master’s degree in Management from the Thunderbird School of Global Management and completed the Advanced Management Program (Executive MBA) at Harvard Business School. He has had an extensive non-profit responsibility as VP of EPFIA (Europe Pharma Association) for three years as well as chairing the French pharma association G5 for six years. Marc de Garidel is a recipient of the French Legion of Honor.
About CinCor
CinCor, founded in 2018, is a clinical-stage biopharmaceutical company with a mission to bring innovation to the pharmaceutical treatment of cardio-renal diseases. Its lead asset, CIN-107, a first-in-class aldosterone synthase inhibitor, is in clinical development for the treatment of hypertension and primary aldosteronism. CinCor completed a $50 million Series A financing in 2019 and is financed by Sofinnova Investments, Sofinnova Partners, and 5AM Ventures.
For more information: https://cincor.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.